Latest Conference Articles

The observational GALAXY study has shown that using a ctDNA assay may help identify which patients with colorectal cancer have the potential to derive benefit from adjuvant chemotherapy.

CheckMate 9X8 trial results indicate a progression-free survival improvement with nivolumab that was not statistically significant.

Promising study results support continued research of T-DXd in patients with HER2-positive mCRC while the risk of potential ILD/pneumonitis requires monitoring.

Afsaneh Barzi, Md, PhD, provides background on a new phase 1/2 studying exploring the combination of regorafenib and pembrolizumab in patients with refractory microsatellite stable colorectal cancer.

Patients with advanced hepatocellular carcinoma achieved notable improvements in survival and responses following treatment with transarterial chemoembolization and lenvatinib.

In a phase 1/2 study demonstrated that the combination of encorafenib, cetuximab, and nivolumab was well tolerated and led to responses in patients with microsatellite stable BRAFV600E metastatic colorectal cancer.

Results from a large trial evaluating the combination of pembrolizumab and regorafenib showed durable results for patients with microsatellite stable colorectal cancer.

Treatment with a triplet combination of pembrolizumab, binimetinib and bevacizumab was associated with an observed clinical benefit in patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer.

Phase 1b/2 data for the combination of onvansertib with FOLFIR I and bevacizumab appear promising for paints with KRAS-mutant metastatic colorectal cancer.

Olaparib and pembrolizumab appear to be a safe and tolerable combination therapy for patients with advanced cholangiocarcinoma.

According to new KEYNOTE-590 study findings, pembrolizumab and chemotherapy as a treatment for patients with locally advanced and metastatic esophageal cancer showed clinical benefit.

In subjects with recurrent hepatocellular carcinoma who underwent liver transplant, both progression-free survival and overall survival were prolonged with manageable adverse events.

In the CheckMate 649 trial, durable survival benefit was achieved with Nivolumab plus chemotherapy in patients with gastric or gastroesophageal junction cancer.

The combination of transarterial chemoembolization, lenvatinib, and PD-1 checkpoint blockade demonstrated tolerable safety and efficacy in patients with unresectable advanced hepatocellular carcinoma.

Sintilimab treatment in pancreatic cancer shows mixed efficacy results in the phase 3 CISPD3 trial.

In the phase 3 KEYNOTE-394 trial, pembrolizumab and best supportive care prolongs survival in patients.

During the 2022 Gastrointestinal Cancers Symposium, Zev A. Wainberg, MD, predicts how gastric cancer treatment will look in the near future.

In a phase 3 study, patients with biliary tract cancer who received adjuvant oral fluoropyrimidine derivative S-1 lived longer than patients who underwent surgery.

According to updated findings from a cohort of the KRYSTAL-1 trial adagrasib may be active in previously treated KRAS G12C¬–mutant gastrointestinal tumors.

Results from the phase 3 KEYNOTE-062 study appear mixed for both pembrolizumab monotherapy versus chemotherapy and pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Single nucleotide polymorphisms such as NOTCH1, SEMA4D, NLRC5, and IL6R, may be predictive of nivolumab toxicity in advanced gastric cancer.

Updated survival results from the phase 2 DESTINY-Gastric01 trial reveal the survival benefit of trastuzumab deruxtecan HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.

Two oncologists explain how patients can better understand the NCCN Clinical Practice Guidelines.

Two oncologists discuss the NCCN Clinical Practice Guidelines for triple-negative breast cancer.

Liso-cel was found to improve quality of life in patients with large B-cell lymphoma compared with standard of care.

Updated findings from the CARTITUDE-1 trial presented at the 2021 ASH Annual Meeting and Exposition show that the use of a CAR T-cell therapy resulted in durable responses that lasted at nearly 2 years of follow-up across most subgroups with relapsed/refractory multiple myeloma.

The combination of low-dose acalabrutinib/rituximab showed to be feasible and effective in CLL/SLL.

Acalabrutinib demonstrated a favorable risk-benefit profile in R/R CLL.

Compared with ibrutinib, acalabrutinib demonstrates less toxicity burden In CLL.

Magrolimab will be tested in combination with various antileukemia therapies at multiple disease points, such as the first line and remission stages.